Covid-19 vaccine maker Bharat Biotech said on Tuesday that the supply price of Covaxin to the Central government at Rs 150 per dose is not sustainable in the long run.
The Hyderabad-based firm said a higher price in private markets is required to offset part of the costs.
The Centre's supplying price is pushing the pricing structure for the private sector upward, the firm said.
Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins, among few others, contribute to higher pricing of Covaxin to the private sector, Bharat Biotech said.
The firm is currently supplying Covaxin at Rs 150 per dose to the Centre, Rs 400 to the state government and Rs 1,200 to private hospitals.